1. Introduction {#sec1}
===============

Sporadic inclusion body myositis (sIBM) is the most common myopathy among people aged \>45 years, presenting a characteristic pattern of progressive muscle weakness and atrophy in both proximal and distal muscles, particularly in knee extensors and wrist and finger flexors ([@bib26]). Muscle pathology in sIBM indicates a combination of inflammatory and degenerative features such as rimmed vacuoles, sarcoplasmic inclusions, and the deposition of degenerative proteins in affected muscle as pathologic hallmarks, which are features that differentiate sIBM from other muscle disorders ([@bib26]). Electromyography shows a myopathic and neurogenic pattern in some sIBM patients ([@bib25]), which resembles some hereditary inclusion body myopathies (hIBMs) and motor neuron diseases ([@bib8], [@bib25]). Genes have been identified as associated with hIBMs, and genetic susceptibility factors could also be involved in the pathogenesis of sIBM. In addition to the known hIBM genes, genes encoding for the proteins abnormally accumulated in sIBM muscle are of great interest ([@bib11]), as many of these proteins, such as amyloid-β, hyperphosphorylated tau, p62, and transactive response (TAR) DNA-binding protein-43 (TDP-43), have also been associated with neurodegenerative diseases including Alzheimer\'s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson\'s disease. Furthermore, several studies have shown that the major histocompatibility complex (MHC)--related genes are dysregulated in sIBM ([@bib11]). However, no genetic factors have yet been confirmed as associated with sIBM ([@bib11], [@bib12]).

P62, also known as sequestosome 1 (SQSTM1), has been recognized as a strong biomarker in muscle with a high sensitivity and specificity for sIBM ([@bib4]). Genetic variants in *SQSTM1* had not been investigated in sIBM until a recent study using targeted next-generation sequencing in a group of 79 patients ([@bib41]). In that study, only a common *SQSTM1* polymorphism was found, unlikely contributing to a rare disease. A recent study reported a splice donor variant in *SQSTM1* in a family with an autosomal dominant distal myopathy and also in an unrelated patient with sporadic distal myopathy ([@bib5]). In addition, mutations in *SQSTM1* are well known to be associated with familial and/or sporadic Paget disease of bone, ALS, and frontotemporal dementia (FTD) ([@bib10], [@bib22], [@bib23], [@bib24], [@bib30], [@bib34]). Mutations in valosin-containing protein (*VCP*) gene are known to cause an inherited form of IBM with Paget disease and frontotemporal dementia (IBMPFD) ([@bib13], [@bib40]) and have also been reported in cases with ALS and FTD ([@bib18], [@bib21]). Two missense mutations in *VCP* have been recently identified in 2 unrelated IBM patients, one with sIBM and another with family history for late-onset dementia ([@bib41]).

These findings, along with denervation in muscle electromyography of sIBM patients, suggest a possible genetic overlap between sporadic and IBM-like myopathies and also neurodegenerative diseases. To thoroughly investigate the contribution of *SQSTM1* and *VCP* genes in sIBM, we investigated these 2 genes using whole-exome sequencing data from 181 sIBM patients, which was produced as a part of an International IBM Genetics Consortium.

2. Materials and methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

This study is part of the International IBM Genetics Consortium, a Muscle Study Group--endorsed project, which currently has members from 17 specialized centers in 7 countries around the world. For this whole-exome sequencing Consortium study, DNA samples from a total number of 181 sIBM patients were collected from 11 centers. Patients diagnosed with sIBM had to have an sIBM diagnosis according to a muscle diseases expert and also had to fulfil the Griggs criteria ([@bib14], [@bib38]), the European Neuromuscular Center 2000 criteria ([@bib2]), or the MRC 2010 criteria ([@bib16]). Neuropathologically healthy controls (*N* = 235) aged \>60 years were used as an internal aged control group to compare with our sIBM cohort. The study was approved by the National Research Ethics Service Committee London---Queen Square (research ethics committee reference: 12/LO/1557).

2.2. Genetic and bioinformatic analysis {#sec2.2}
---------------------------------------

Whole-exome sequencing data were generated for 181 sIBM DNA samples as previously described ([@bib28]). In this study, we used a candidate gene approach on these whole-exome sequencing data to investigate variants in *SQSTM1* and *VCP* genes. We excluded all synonymous variants, and all common variants with a population frequency \>1% were identified in the 1000 Genomes project ([www.1000genomes.org/](http://www.1000genomes.org/){#intref0010}), in the Exome Variant Server (EVS) database ([evs.gs.washington.edu/EVS/](http://evs.gs.washington.edu/EVS/){#intref0015}), in the Exome Aggregation Consortium (ExAC) Browser ([exac.broadinstitute.org/](http://exac.broadinstitute.org/){#intref0020}), and in the internal aged controls, as these variants less likely play a role in a rare disease. The filtered variants were confirmed by the conventional Sanger sequencing. The allele frequency of each variant found in sIBM was compared with the ExAC database using Fisher test. The pathogenicity of these variants was evaluated using the following in silico prediction tools: SIFT ([@bib42]), MutationTaster ([@bib43]), and PolyPhen2 ([@bib44]). Genomic evolutionary rate profiling (GERP++) scores were used to estimate the conservation of each variant in multispecies alignments, with higher scores indicating the most conserved nucleotide positions ([@bib45]).

2.3. Messenger RNA expression and real-time quantitative polymerase chain reaction validation {#sec2.3}
---------------------------------------------------------------------------------------------

Available flash frozen muscle biopsy tissues from 6 sIBM subjects with variants in *SQSTM1* or *VCP* and 8 controls that were kindly provided by the MRC Sudden Death Brain and Tissue Bank in Edinburgh, UK, were used for the gene expression analysis. Total RNA was isolated from muscle tissue using the miRNeasy kit (Qiagen, Crawley, UK), and the concentration, purity, and integrity of each RNA sample were assessed as previously described ([@bib39]).

Whole-genome expression profiling was performed using the Illumina HumanHT-12 v4 Expression BeadChip (Illumina, Inc, USA) on 3 patients with *SQSTM1* variants (cases 1, 3, and 4), 2 patients with *VCP* variants (cases 6 and 7), and 5 age- and gender-matched controls. Raw expression data were log2 transformed and quantile normalized, and differential expression analysis (patients with *SQSTM1* variants vs. controls and all the patients vs. controls) was performed using the limma Bioconductor package ([@bib32]). Genes were considered differentially expressed and used in further analysis, when false discovery rate--adjusted *p* value was \<0.05 and absolute log2 fold change was \>0.2. Functional enrichment analysis for Gene Ontology terms, KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways, and Human Phenotype Ontology terms was performed using g:Profiler ([biit.cs.ut.ee/gprofiler/](http://biit.cs.ut.ee/gprofiler/){#intref0025}). Among the upregulated genes, 3 genes associated with inflammation markers (*HLA*-*A*, *CD74*, and *HLA*-*DRA*) were selected for validation using real-time quantitative polymerase chain reaction (RT-qPCR). Briefly, total RNA (600 ng) from the 6 cases and 8 controls was reverse transcribed into complementary DNA using random primers from High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA). Three replicates per sample were assayed for each target gene using Fast SYBR Green PCR Kit (Applied Biosystems) and run in a QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). Details on primers and RT-qPCR conditions are available on request. Cyclophilin (*PPIA*) was selected as the reference gene. The 2^−ΔΔCt^ method ([@bib37]) was used for Ct normalization for each gene and determination of fold changes in gene expression between patients and controls. Mann-Whitney *U* test was performed to analyze the difference of relative gene expression between patient groups and controls. For all the analyses, *p* value \<0.05 was considered statistically significant. Statistical analysis was performed using SPSS Statistics 22 (IBM, USA).

3. Results {#sec3}
==========

From the entire cohort of 181 sIBM patients, 150 (82.9%) were Caucasians and 16 (8.8%) were from other ethnicities, including Asian Chinese, the Indian subcontinent, and Black Africans (ethnicity information was unavailable for 15 patients). The majority of sIBM patients were male (65.7%). Age of onset, which was collected retrospectively, ranged from 31 to 85 years (mean 59.6 ± 9.6 years). The mean age of the 235 healthy aged controls was 79.1 ± 8.5 years, ranging from 60 to 102 years, and similarly to the sIBM cohort, the majority were also male (61.7%).

In this sIBM cohort, 4 rare missense variants in the *SQSTM1* gene (ENST00000389805) were found in 4 patients ([Table 1](#tbl1){ref-type="table"}). Two rare missense variants in the *VCP* gene (ENST00000358901) were found in 3 sIBM patients. Of note, the frequency of the variants *SQSTM1* p.G194R and *VCP* p.R159C was significantly higher in our sIBM cohort compared with the ExAC database (Fisher exact test, *p* = 0.018 and *p* = 5.288 × 10^−5^, respectively). These 2 variants were absent in the other population databases and in our aged control group. From the 6 rare variant we found, 4 ([Table 1](#tbl1){ref-type="table"}) had been previously reported in patients with ALS ([@bib1], [@bib34]). Among them, the *SQSTM1* p.P392L is also known to be the most frequent *SQSTM1* mutation in PDB ([@bib23]) and has also been reported in cases with FTD ([@bib24]) and normal tension glaucoma ([@bib36]), whereas *VCP* p.I27V and p.R159C have also been found in patients with IBMPFD ([@bib6], [@bib33]), and the *VCP* p.I27V has also been recently reported in one sIBM patient ([@bib41]). The *SQSTM1* p.A117V was reported in one early-onset AD patient ([@bib7]). Variants found in sIBM patients were absent in our internal aged controls except *SQSTM1* variants previously associated with ALS (p.P392L and p.K238E, [Table 1](#tbl1){ref-type="table"}). With the exception of *SQSTM1* p.A117V, all these variants are located at conserved positions among species further suggesting they are functionally relevant. The variants found in our cohort and in previous studies are shown in [Fig. 1](#fig1){ref-type="fig"}.

[Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"} summarize the demographic, clinical, and muscle biopsy characteristics of the patients carrying *SQSTM1* and *VCP* variants. The 7 sIBM cases fulfilled the MRC 2010 diagnostic category of pathologically defined, clinically defined, or possible sIBM. There was also no family history of muscle diseases, and none of the 7 patients and their families showed evidence of bone or cognitive problems.

[Fig. 2](#fig2){ref-type="fig"} illustrates the pathologic features of muscle biopsies observed in patients carrying variants in *SQSTM1* only because of the availability of the biopsy images. P62-positive inclusions were found in 3 patients with *SQSTM1*. Patients with *SQSTM1* variants showed a global upregulation of MHC-I (diffuse pattern, [Fig. 2](#fig2){ref-type="fig"}G) compared with the healthy control ([Fig. 2](#fig2){ref-type="fig"}H).

To further understand molecular changes occurring in sIBM, particularly those related to the variants in *SQSTM1* and *VCP*, we have performed whole-genome expression analysis. Most of the differential expressed genes were found comparing the *SQSTM1* sIBM patient group with controls ([Supplementary Tables 1 and 2](#appsec1){ref-type="sec"}), with 33 upregulated and 7 downregulated genes. The small number of available tissue samples (*n* = 2) from patients with *VCP* variants prevented statistical analysis of this sIBM patient group. The expression of *SQSTM1* and *VCP* did not show significant differences between any patient group and controls, but a significant upregulation of MHC genes (class I \[*HLA*-*A*\] and class II \[*CD74* and *HLA*-*DRA*\]) was seen in the group of patients carrying *SQSTM1* variants ([Supplementary Table 2](#appsec1){ref-type="sec"}). RT-qPCR analysis of those MHC genes validated their upregulation in sIBM; this was particularly evident comparing the *SQSTM1* group with the controls, with significant upregulation of all analyzed genes ([Fig. 3](#fig3){ref-type="fig"}). Functional enrichment analysis of upregulated genes in the *SQSTM1* patient group showed a significant overrepresentation of several Gene Ontology terms related with immune response, MHC protein complex, and endosome vesicles and KEGG pathways mostly related to inflammatory, autoimmune, and infectious diseases ([Supplementary Table 3](#appsec1){ref-type="sec"}). The small number of dysregulated genes found in the expression microarray analysis data prevented functional enrichment analysis for other comparison groups.

4. Discussion {#sec4}
=============

Using whole-exome sequencing, we identified rare missense variants in the *SQSTM1* and *VCP* genes in 7 sIBM cases. The frequency of patients with rare *SQSTM1* and *VCP* variants in the sIBM cohort was 4.0%. Two independent cases have previously been reported with *VCP* variants ([@bib41]), but our study extends this finding in a larger cohort of sIBM patients. Regarding *SQSTM1*, this is to our knowledge the first report where possible pathogenic variants in this gene are observed in sIBM patients.

The *SQSTM1* gene encodes for sequestosome 1 and/or p62 (referred as p62 in the article), which is a multifunction protein participating in a number of different biological pathways ([@bib20]), including the autophagy pathway and various transduction pathways such as nuclear factor-kappaB signaling and apoptosis. Mutations in *SQSTM1* were first identified in PDB ([@bib23]), a chronic disease of bone that can cause skeletal deformity and fractures, and account for 25%--50% of familial and 5%--10% of sporadic PDB patients ([@bib31]). In addition, mutations in *SQSTM1* are also known to contribute to 1%--3.5% of patients with ALS/FTD with or without familial history ([@bib34]), a similar frequency to the one we found in our sIBM cohort. Mutations in *SQSTM1* are widespread along the gene ([Fig. 1](#fig1){ref-type="fig"}A), but the missense mutation p.P392L located in the C-terminal ubiquitin-associated domain, where most mutations lie in, is the most frequent *SQSTM1* mutation in all the different clinical phenotypes ([@bib10], [@bib23]). A mouse model with *sqstm1* p.P394L mutation ([@bib9]), equivalent to *SQSTM1* p.P392L in humans, developed a human PDB-like phenotype and showed dysregulation of autophagy and enhanced autophagosome formation. The *SQSTM1* p.K238E has also been reported in one sporadic ALS ([@bib34]) and lies in a tumor necrosis factor receptor--associated factor 6 (TRAF6)--binding site---where p62 interacts with TRAF6, a critical component of the nuclear factor-kappaB pathway in response to multifactors, including proinflammatory cytokines ([@bib10]). The *SQSTM1* p.G194R has not been observed in other diseases and was absent in our aged controls, and it is worth mentioning that it has been found overrepresented our sIBM cohort. Although the *SQSTM1* p.A117V is predicted as benign, it was absent in our aged controls and recently was reported in a patient with early-onset AD ([@bib7]) and thus cannot be excluded as a risk factor for sIBM.

The *VCP* gene encodes for the ATPase valosin-containing protein, which plays a role in proteasomal degradation of misfolded proteins ([@bib29]). *VCP* is also involved in critical signaling pathways, membrane fusion, cell cycle controls, and more importantly facilitating a cargo sorting via endosomal and/or autophagy pathway ([@bib29]). Mutations in *VCP* are known to cause IBMPFD ([@bib40]), Parkinson\'s disease ([@bib27]), and are also associated with ALS with or without FTD ([@bib18]). The *VCP* p.I27V variant has been previously reported as potentially pathogenic ([@bib27], [@bib33]) and was recently found in another patient with sIBM ([@bib41]). Functional analysis of this variant showed an increase in p62 and LC3II protein levels ([@bib41]), suggesting it may cause disruption in autophagosome maturation ([@bib19]). The *VCP* p.R159C found to be overrepresented in our sIBM cohort has been previously reported as pathogenic and associated with IBMPFD ([@bib3]) and sporadic ALS ([@bib1]). Two additional mutations were also found at this amino acid residue in familial ALS (p.R159G) ([@bib18]) and IBMPFD (p.R159H) ([@bib15]). The *VCP* p.R159C lies within the highly conserved CDC48 domain of the protein ([Fig. 1](#fig1){ref-type="fig"}B), which is involved in ubiquitin-binding and protein-protein interaction, and a hotspot for *VCP* mutations ([@bib3]).

We reviewed the clinical and pathologic details of all sIBM patients with *SQSTM1* and *VCP* variants and confirmed that none of them had developed symptoms of PDB, FTD, or ALS and none had family history of these diseases or family history of muscle weakness. VCP staining was not available for all the patients, but p62-positive inclusions were seen in all 3 biopsies where p62 staining was available, including 3 sIBM with *SQSTM1* p.P392L, p.A117V, and p.G194R.

The expression levels of either *SQSTM1* or *VCP* messenger RNA were not significantly altered in patients compared with controls, suggesting that the missense variants found in these patients did not alter the corresponding gene expression at the messenger RNA level. P62 and VCP aggregates in the muscle could be a result of increased protein stability, dysfunction of other factors along the proteasomal or lysosomal pathway, or both ([@bib35]).

The MHC class I (*HLA*-*A*) and II (*HLA*-*DRA*) genes were significantly upregulated in patients compared with controls by RT-qPCR, which is consistent with a previous study ([@bib17]), and the other MHC class II gene (*CD74*) was significantly upregulated only in the *SQSTM1* patient group. The statistical analysis could not be carried out for the *VCP* patient group because of small sample size, but there was also a trend for the upregulation of these inflammation markers. The more pronounced upregulation observed in the *SQSTM1* sIBM patient group than in the *VCP* patient group. This is the first time that different expression level of inflammation markers between patients with sIBM is suggested. Although further cases should be analyzed, the MHC expression could be a potential differentiating factor that directs the clinical phenotype of *SQSTM1* or *VCP* toward sIBM as opposed to the other neurodegenerative conditions. Additional analysis in muscle and other tissues of patients carrying *SQSTM1* or *VCP* mutations without symptomatic sIBM but other phenotypes is also necessary in the future to confirm this hypothesis.

In conclusion, we report for the first time likely pathogenic *SQSTM1* variants and expand the spectrum of *VCP* variants in sIBM. Our findings suggest that variants in these genes constitute genetic susceptibility factors for sIBM and for other multisystem proteinopathy phenotypes. The findings from this study also expand the clinicopathologic spectrum of diseases associated with *SQSTM1* and *VCP* genes, and the overlap between sIBM and IBMPFD, ALS, and/or FTD suggests that muscle and brain diseases share similar pathogenic pathways that may be important for further biomarkers, genes, and therapeutic target discovery. Further investigation of the sIBM whole-exome sequencing data is still ongoing and data from this international collaboration will likely reveal further findings.
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![Mutations and/or variants in sequestosome 1 (*SQSTM1*) and valosin-containing protein (*VCP*) genes and their protein domains. (A) Mutations and/or variants found in *SQSTM1* gene and protein domains. (B) Mutations and/or variants found in *VCP* gene and the protein domains. The ones above the gene structure were reported in the previous studies. The ones below were identified in our sporadic inclusion body myositis cohort, and the one labeled in red was not reported in other diseases before. Abbreviations: LIR, LC3-interaction region; PB1, Phox and Bem1p domain; TRAF6, tumor necrosis factor receptor--associated factor 6 binding site; UBA, ubiquitin-associated domain; UTR, untranslated region; ZZ, zinc finger domain.](gr1){#fig1}

![Pathologic features observed in sporadic inclusion body myositis patients. There was variation in fiber size with endomysial inflammation, increased internal nucleation, and fiber regeneration (A, hematoxylin and eosin). Rimmed vacuoles were found in all cases (B, Gomori trichrome). The inflammatory infiltrate contains T lymphocytes (C, CD3). A ragged red fiber was observed in case 2 (D, Gomori trichrome). Cytochrome *c* oxidase negative fibers were identified (E, cytochrome oxidase and/or succinic dehydrogenase). P62 immunoreactive sarcoplasmic inclusions were identified (F) in addition to sparse intranuclear inclusions (arrow and inset). Major histocompatibility complex class I was diffusely increased in patients with sequestosome 1 (*SQSTM1*) variants (G) in comparison with a normal control (H). Scale bar represents 50 μm in A, C, G, and H; 25 μm in B, D, and F; and 10 μm in the inset in F. Panels A and G are from Case 1; panels B--F are from case 2.](gr2){#fig2}

![Scatter plot illustrating distribution of the fold change for the expression of 3 major histocompatibility complex genes in sporadic inclusion body myositis groups compared with controls as determined by real-time quantitative polymerase chain reaction. All expression levels were normalized to the expression of the reference gene, *PPIA*, and relative to the mean normalized expression of all the controls. The solid black lines denote the medians. Only significant Mann-Whitney *U* test *p* values (\<0.05) regarding comparisons of patient groups with controls are shown. Abbreviations: *CD74*, CD74 molecule, major histocompatibility complex, class II invariant chain; *HLA-A*, major histocompatibility complex, class I, A; *HLA-DRA*, major histocompatibility complex, class II, DR alpha.](gr3){#fig3}

###### 

*SQSTM1* and *VCP* rare genetic variants in patients with sIBM

Table 1

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case ID          Gene and region   Variants (heterozygous)   MAF in 235 neuropathologic controls (%)   MAF in 1000 genomes (%)   MAF in ExAC (%)   MAF in sIBM cohort (%)   GERP++ score   PolyPhen prediction   Known in other diseases
  ---------------- ----------------- ------------------------- ----------------------------------------- ------------------------- ----------------- ------------------------ -------------- --------------------- ---------------------------------------
  Case 1 (sIBM)    *SQSTM1*\         p.P392L (rs104893941)     0.213                                     0.46                      0.089             0.275                    4.43           Pathogenic            Familial PDB and ALS
                   Exon 8                                                                                                                                                                                          

  Case 2 (sIBM)    *SQSTM1*\         p.A117V (rs147810437)     0                                         0.18                      0.152             0.275                    −5.17          Benign                Early-onset AD
                   Exon 3                                                                                                                                                                                          

  Case 3 (sIBM)    *SQSTM1*\         p.G194R                   0                                         ---                       0.0017            0.275                    3.65           Possibly damaging     ---
                   Exon 4                                                                                                                                                                                          

  Case 4 (sIBM)    *SQSTM1*\         p.K238E (rs11548633)      0.638                                     0.32                      0.242             0.275                    3.87           Possibly damaging     ALS
                   Exon 5                                                                                                                                                                                          

  Case 5 (sIBM)    *VCP*\            p.I27V (rs140913250)      0                                         0.09                      0.054             0.275                    5.71           Benign                IBMPFD, ALS, and PD
                   Exon 2                                                                                                                                                                                          

  Case 6 (sIBM)\   *VCP*\            p.R159C                   0                                         ---                       0.00082           0.549                    4.62           Possibly damaging     IBMPFD, IBM with PD, and sporadic ALS
  Case7 (sIBM)     Exon 5                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Key: A, alanine; AD, Alzheimer\'s disease; ALS, amyotrophic lateral sclerosis; C, cysteine; E, glutamic acid; ExAC, Exome Aggregation Consortium; G, glycine; GERP, genomic evolutionary rate profiling; I, isoleucine; IBMPFD, inclusion body myopathy with Paget disease and frontotemporal dementia; K, lysine; L, leucine; MAF, minor allele frequency; P, proline; PD, Parkinson\'s disease; PDB, Paget disease of bone; R, arginine; sIBM, sporadic inclusion body myositis; *SQSTM1*, sequestosome 1; V, valine; *VCP*, valosin-containing protein.

###### 

Demographic and clinical features of sIBM patients carrying variants in *SQSTM1* and *VCP* genes

Table 2

  Features                            Case 1      Case 2      Case 3                Case 4      Case 5      Case 6      Case 7
  ----------------------------------- ----------- ----------- --------------------- ----------- ----------- ----------- -----------
  Sex                                 F           M           M                     F           M           F           M
  Ethnicity                           Caucasian   Caucasian   Indian subcontinent   Caucasian   Caucasian   Caucasian   Caucasian
  Age at onset                        45          50          71                    57          85          74          48
  Family history                      −           −           −                     −           −           −           −
  Finger flexor weakness              \+          \+          \+                    \+          \+          \+          \+
  Weakness of KE \> HF                −           −           \+                    \+          UNK         −           −
  Weakness of FF \> SA                \+          \+          \+                    \+          UNK         \+          \+
  Weakness of WF \> WE                \+          \+          \+                    −           UNK         −           −
  PDB                                 −           −           −                     −           −           −           −
  ALS                                 −           −           −                     −           −           −           −
  FTD                                 −           −           −                     −           −           −           −
  Parkinson\'s disease                −           −           −                     −           −           −           −
  Elevated CK (×ULN)                  \+ (≤15)    \+ (≤15)    \+ (≤15)              −           −           N/A         \+ (≤15)
  Neurophysiological investigation    Myopathic   Myopathic   Myopathic             N/A         UNK         N/A         N/A
  MRC 2010 sIBM diagnostic category   PAD         PAD         PAD                   CLD         PO          PO          PO

Key: ALS, amyotrophic lateral sclerosis; CK, creatine kinase; CLD, clinically defined; F, female; FF, finger flexion; FTD, frontotemporal dementia; HF, hip flexion; KE, knee extension; M, male; N/A, not available; PAD, pathologically defined; PDB, Paget disease of bone; PO, possible; SA, shoulder abduction; sIBM, sporadic inclusion body myositis; *SQSTM1*, sequestosome 1; ULN, upper limit of normal; UNK, unknown; *VCP*, valosin-containing protein; WE, wrist extension; WF, wrist flexion.

###### 

Main muscle biopsy features of sIBM patients carrying variants in *SQSTM1* and *VCP* genes

Table 3

  Muscle biopsy features                           Case 1   Case 2   Case 3   Case 4   Case 5   Case 6   Case 7
  ------------------------------------------------ -------- -------- -------- -------- -------- -------- --------
  Endomysial exudate                               \+       \+       \+       \+       \+       \+       \+
  MHC-I upregulation                               \+       \+       \+       \+       \+       \+       \+
  Partial invasion                                 \+       \+       \+       −        \+       −        −
  Rimmed vacuoles                                  \+       \+       \+       \+       \+       −        −
  p62 (sarcoplasmic and intranuclear inclusions)   \+       \+       \+       N/A      N/A      N/A      N/A
  TDP-43                                           N/A      \+       N/A      N/A      N/A      N/A      N/A
  15--18 (or 16--21) nm filaments                  N/A      N/A      N/A      −        N/A      N/A      N/A
  COX-deficient fibers                             \+       \+       −        \+       −        \+       \+

Key: COX, cytochrome *c* oxidase; MHC, major histocompatibility complex; N/A, not available; sIBM, sporadic inclusion body myositis; *SQSTM1*, sequestosome 1; TDP-43, TAR DNA-binding protein-43; *VCP*, valosin-containing protein.

[^1]: Equally contributed to the work.
